Publication:
Discordance of intrinsic subtype between primary tumor and lymph node metastasis in breast cancer patients

Simple item page
dc.contributor.authorTomoko Yamamoto
dc.contributor.authorYoji Nagashima
dc.contributor.authorTakako Kamio
dc.contributor.authorKiyomi Horiuchi
dc.contributor.authorTakahiro Okamoto
dc.contributor.authorYoko Omi
dc.contributor.departmentBiología Celular e Histología
dc.date.accessioned2026-02-16T15:40:05Z
dc.date.available2026-02-16T15:40:05Z
dc.date.issued2026
dc.description.abstractThe heterogeneity of cancer cells between primary breast tumors and lymph node (LN) metastases at the initial therapy remains unclear. This study aimed to determine whether intrinsic subtypes of LN metastasis differ from those of primary breast tumors and how much additional information is obtained. Ninety-three breast cancer cases with LN metastasis were enrolled in the study. Immunohistochemistry for ER, PgR, HER2, and Ki-67 was performed for primary breast tumors and the largest LN metastases. The intrinsic subtype was determined as luminal A (ER+, PgR+, HER2-, Ki-67 index ≤20%), luminal B (ER+, HER2-, PgR- or PgR+, and Ki-67 index >20%), luminal B HER2 rich (ER+, HER2+), HER2 (ER-, HER2+), and triple-negative (ER-, PgR-, HER2-). The discordance ratios for intrinsic subtypes between the primary tumor and LN metastasis were analyzed. The discordance ratios for ER, PgR, HER2, and Ki 67 were 0/93 (0%), 7/93 (7.5%), 2/93 (2.2%), and 10/93 (10.8%), respectively. The discordance ratio for the intrinsic subtype was 9/93 (9.7%). Considering the intrinsic subtype of LN metastasis, the effects of additional chemotherapy and anti-HER2 therapy could be expected in 4/93 (4.3%) and 1/93 (1.1%) patients, respectively. The discordance ratio for the intrinsic subtype between the primary breast tumor and LN metastasis was 9.7%. Considering the intrinsic subtype of LN metastasis, additional medical therapy could be expected to be effective in 5/93 (5.4%) breast cancer cases with LN metastasis. Immunohistochemistry of metastatic LNs may be useful for planning adjuvant therapy when the analysis of the primary site is inconclusive.
dc.formatapplication/pdf
dc.format.extent8
dc.identifier.doihttps://doi.org/10.14670/HH-18-989
dc.identifier.eissn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/205963
dc.languageeng
dc.relationUniversidad de Murcia, Departamento de Biologia Celular e Histiologia
dc.relationSin financiación externa a la Universidad
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectLymph node metastasis
dc.subjectIntrinsic subtype
dc.subjectBreast cancer
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titleDiscordance of intrinsic subtype between primary tumor and lymph node metastasis in breast cancer patients
dc.typeinfo:eu-repo/semantics/article
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Omi-41-431-438-2026.pdf
Size:
7.37 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology, Vol.41, Nº3, (2026)